Compared to CD19+ normal B cells, mouse BCR-ABL+ B-ALL cells were significantly more susceptible to the treatment of the two JNK inhibitors (Fig. 2f, g). The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.